Furthermore, ANGPTL8 levels were associated with poor prognosis in KIRC, UCEC, and LUSC patients (Xu et al., 2021) but with longer overall survival or disease-free survival time in CHOL, GBM, sarcoma (SARC), uveal melanoma (UVM), BLCA, BRCA, pheochromocytoma and paraganglioma (PCPG), thymoma (THYM), uterine carcinosarcoma (UCS) patients (Xu et al., 2021; Iqbal et al., 2023) and PAAD (Taherkhani et al., 2020) (Table 1). Here, ANGPTL8 is linked to glioblastoma.